Geographical variability in dabigatran dosing within New Zealand

IF 1.8 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Internal Medicine Journal Pub Date : 2026-08-10 Epub Date: 2026-05-25 DOI:10.1111/imj.70477

Liam T. Berryman, Paul K. L. Chin, Lorna J. Pairman, Milan Sundermann, Matthew Doogue

引用次数: 0

Abstract

Dabigatran etexilate is an oral anticoagulant with increased risk of bleeding at high drug exposure. It is available in three capsule strengths (75, 110 and 150 mg). We analysed New Zealand dispensing data from 2019 to 2023 to compare use between health districts. Overall use was similar across districts. Canterbury had the highest 75 mg use (22.2 vs 1.6–7.6 people per 10 000 in the other districts). This relates to differences in local guidelines, therapeutic drug monitoring and availability of clinical pharmacology services. It is unknown if there are differences in patient outcomes.

查看原文本刊更多论文

新西兰达比加群剂量的地理差异。

达比加群酯是一种口服抗凝剂，在高药物暴露时出血风险增加。它有三种胶囊强度（75,110和150毫克）。我们分析了新西兰2019年至2023年的配药数据，以比较卫生区域之间的使用情况。各地区的总体使用情况相似。坎特伯雷的75毫克使用量最高（22.2人比其他地区的1.6-7.6人每10000人）。这与当地指南、治疗药物监测和临床药理学服务的可用性的差异有关。目前尚不清楚患者预后是否存在差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal Medicine Journal 医学-医学：内科

CiteScore

3.50

自引率

4.80%

发文量

600

审稿时长

3-6 weeks

期刊介绍： The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.